These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

122 related articles for article (PubMed ID: 23298762)

  • 1. Rifaximin plus fibre versus fibre alone in preventing diverticulitis recurrence: a (problematic) trial to tackle an epidemiologically relevant problem.
    Conte D; Orlando S
    Dig Liver Dis; 2013 Feb; 45(2):102-3. PubMed ID: 23298762
    [No Abstract]   [Full Text] [Related]  

  • 2. One year intermittent rifaximin plus fibre supplementation vs. fibre supplementation alone to prevent diverticulitis recurrence: a proof-of-concept study.
    Lanas A; Ponce J; Bignamini A; Mearin F
    Dig Liver Dis; 2013 Feb; 45(2):104-9. PubMed ID: 23092785
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Diverticulitis: new insights on the traditional point of view.
    Moubax K; Urbain D
    Acta Gastroenterol Belg; 2015; 78(1):38-48. PubMed ID: 26118576
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Diverticular disease: what is the best long-term treatment?
    Tursi A
    Nat Rev Gastroenterol Hepatol; 2010 Feb; 7(2):77-8. PubMed ID: 20134488
    [No Abstract]   [Full Text] [Related]  

  • 5. Mesalazine and rifaximin in symptomatic uncomplicated diverticular disease.
    Festi D; Colecchia A
    Am J Gastroenterol; 2009 Feb; 104(2):532. PubMed ID: 19174809
    [No Abstract]   [Full Text] [Related]  

  • 6. Long-term treatment with mesalazine and rifaximin versus rifaximin alone for patients with recurrent attacks of acute diverticulitis of colon.
    Tursi A; Brandimarte G; Daffinà R
    Dig Liver Dis; 2002 Jul; 34(7):510-5. PubMed ID: 12236485
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Meta-analysis: long-term therapy with rifaximin in the management of uncomplicated diverticular disease.
    Bianchi M; Festa V; Moretti A; Ciaco A; Mangone M; Tornatore V; Dezi A; Luchetti R; De Pascalis B; Papi C; Koch M
    Aliment Pharmacol Ther; 2011 Apr; 33(8):902-10. PubMed ID: 21366632
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The influence of rifaximin on diverticulitis rate and quality of life in patients with diverticulosis.
    Banasiewicz T; Francuzik W; Bobkiewicz A; Krokowicz Ł; Borejsza-Wysocki M; Paszkowski J; Studniarek A; Krokowicz P; Grochowalski M; Szczepkowski M; Lorenc Z
    Pol Przegl Chir; 2017 Feb; 89(1):22-31. PubMed ID: 28522790
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Review article: the pathophysiology and medical management of diverticulosis and diverticular disease of the colon.
    Tursi A; Papa A; Danese S
    Aliment Pharmacol Ther; 2015 Sep; 42(6):664-84. PubMed ID: 26202723
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Clinical and pharmacological aspects of rifaximin, local antibiotic therapy in intestinal disorders].
    Gasztonyi B; Hunyady B
    Orv Hetil; 2004 Oct; 145(43):2177-81. PubMed ID: 15575494
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Rifaximin improves symptoms of acquired uncomplicated diverticular disease of the colon.
    Latella G; Pimpo MT; Sottili S; Zippi M; Viscido A; Chiaramonte M; Frieri G
    Int J Colorectal Dis; 2003 Jan; 18(1):55-62. PubMed ID: 12458383
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy of rifaximin in the treatment of symptomatic diverticular disease of the colon. A multicentre double-blind placebo-controlled trial.
    Papi C; Ciaco A; Koch M; Capurso L
    Aliment Pharmacol Ther; 1995 Feb; 9(1):33-9. PubMed ID: 7766741
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Treatment of diverticular disease of the colon and prevention of acute diverticulitis: a systematic review.
    Maconi G; Barbara G; Bosetti C; Cuomo R; Annibale B
    Dis Colon Rectum; 2011 Oct; 54(10):1326-38. PubMed ID: 21904150
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Rifaximin plus mesalazine followed by mesalazine alone is highly effective in obtaining remission of symptomatic uncomplicated diverticular disease.
    Brandimarte G; Tursi A
    Med Sci Monit; 2004 May; 10(5):PI70-3. PubMed ID: 15114281
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Rifaximin and diverticular disease: Position paper of the Italian Society of Gastroenterology (SIGE).
    Cuomo R; Barbara G; Annibale B
    Dig Liver Dis; 2017 Jun; 49(6):595-603. PubMed ID: 28215517
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effectiveness of different therapeutic strategies in preventing diverticulitis recurrence.
    Tursi A; Elisei W; Giorgetti GM; Inchingolo CD; Nenna R; Picchio M; Maiorano M; Penna A; Lecca PG; Brandimarte G
    Eur Rev Med Pharmacol Sci; 2013 Feb; 17(3):342-8. PubMed ID: 23426537
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Diverticulosis/diverticulitis? What are conservative therapy possibilities?].
    Rinas U; Adamek HE
    Med Klin (Munich); 2006 Jan; 101(1):49-57; quiz 58-9. PubMed ID: 16418814
    [No Abstract]   [Full Text] [Related]  

  • 18. Management of diverticular disease: is there room for rifaximin?
    Papi C; Koch M; Capurso L
    Chemotherapy; 2005; 51 Suppl 1():110-4. PubMed ID: 15855755
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Role of rifaximin in the treatment of colonic diverticular disease].
    Moretti A; Spagnolo A; Mangone M; Chiesara F; Aratari A; Papi C; Koch M
    Clin Ter; 2012; 163(1):33-8. PubMed ID: 22362232
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Rationale and evidences for treatment of symptomatic uncomplicated diverticular disease.
    Cuomo R; Cargiolli M; Andreozzi P; Zito FP; Sarnelli G
    Minerva Gastroenterol Dietol; 2017 Jun; 63(2):130-142. PubMed ID: 27973463
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.